Three-Year Extension of Cooperative Research and Development Agreement (CRADA) with NIH’s NIAID for Post-Transplant Lymphoproliferative Disorder (PTLD) | SymBio Pharmaceuticals Limited (4582) timely disclosure

Worth reading

43Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Neutral

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Conditional

How definitive the wording is.

Agreements reached under this partnership

Business alliance

4582SymBio Pharmaceuticals Limited

Alliance partnerNational Institute of Allergy and Infectious Diseases (NIAID) / research team under the National Institutes of Health (NIH)

Details of the alliance

1
Verification of BCV's antiviral activity against Epstein-Barr virus (EBV)
2
Conduct of nonclinical studies targeting EBV-related lymphoproliferative disorders
3
Verification of BCV's therapeutic efficacy using this animal model
4
Accumulation of knowledge toward the start of clinical trials

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner

Business DescriptionCollaborative research and development targeting post-transplant lymphoproliferative disorder (PTLD) and Epstein-Barr virus-related diseases

LocationUnited States

Impact on Business Performance

This matter will have no impact on consolidated results for the fiscal year ending December 2026.

Contract DateApril 2023Contract PeriodThrough April 2029. The CRADA entered into in April 2023 has been extended by 3 years. The automatic renewal provision is Not disclosed.

Agreements reached under this partnership
Item	Details
Name of alliance partner	National Institute of Allergy and Infectious Diseases (NIAID) / research team under the National Institutes of Health (NIH)
Alliance partner's business activities	Collaborative research and development targeting post-transplant lymphoproliferative disorder (PTLD) and Epstein-Barr virus-related diseases
Alliance partner's location	United States
Type of alliance	Business alliance
Details of the alliance	Verification of BCV's antiviral activity against Epstein-Barr virus (EBV), Conduct of nonclinical studies targeting EBV-related lymphoproliferative disorders, Verification of BCV's therapeutic efficacy using this animal model, Accumulation of knowledge toward the start of clinical trials
Contract Period	Through April 2029. The CRADA entered into in April 2023 has been extended by 3 years. The automatic renewal provision is Not disclosed.
Contract Date	April 2023
Impact on Business Performance	This matter will have no impact on consolidated results for the fiscal year ending December 2026.

Items this document does not state (15)

Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To verify BCV's therapeutic efficacy and accumulate knowledge toward the start of clinical trials.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.